We had an example of that last week in Europe. In 2021, they came forward with an assessment for TiO2, a substance that has been in place for many years. The industry challenged it. It went to the European Court of Justice and it was overturned last week.
That's a substance that's been around and understood, but they moved forward with a category 2 carcinogen designation in the EU, and it was turned down. That was based on only one study, or several very limited studies. Had it been looked at more substantively, maybe it would have proceeded further, but that's a recent example of going too far too quickly, without the data you need. It was turned down by the European Court of Justice.